NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.23 +0.85 (+1.08%) GOLD FUTURES
2,316.20 -8.00 (-0.34%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,286.94 -1,161.10 (-2.30%)
HYTN Innovations Inc. (HYTN.CN)
| Previous close | 0.2550 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.2550 - 0.2550 |
| 52-week range | 0.0050 - 0.3900 |
| Volume | |
| Avg. volume | 51,285 |
| Market cap | 19.724M |
| Beta (5Y monthly) | 7.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireHYTN Welcomes U.S. Recommendation to Reclassify Cannabis, Foresees Growth
VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, applauds the recent formal recommendation by the U.S. Justice Department, endorsed by the Drug Enforcement Agency (DEA), to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This historic shift, pending revie
- GlobeNewswire
HYTN Innovates GMP Stability Programs, Sets Industry Benchmark
VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, is pleased to announce significant advancements in its Good Manufacturing Practice (GMP) stability programs. Stability programs constitute a cornerstone of all GMP guidelines and are vital for achieving GMP certification.
- GlobeNewswire
HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, welcomed Health Canada’s conduct of a Drug Establishment License (DEL) audit. The audit, which aims to expand the Company's Good Manufacturing Practices (GMP) capabilities, follows the recent achievement of GMP certification for HYT
